Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-177

And just to reinforce the point:

US03-008 is Cohort 3 and is intravenous without pembro. At the Oct data cut-off, 120 days for this patient and achieved stable disease. Tumor reduction still evident in the Dec cut. so there's no progression here. Absolute bullsh1t to suggest otherwise.

"typically", "highly likely", "likely", "could mean" - all very speculative.

the only worthy statement in the whole piece:

"the nature of research is exploratory and ongoing, so the addition of cohorts and more patient data may prove to be in favor of or work against the clinical efficacy of CF33 in patients."